Clinical Equivalence of Budesonide HFA MDI Versus Budesonide Turbuhaler in Mild to Moderate Chinese Asthma Patients
Condition: Asthma Interventions: Drug: Budesonide 200 microgram/Puff, HFA MDI; Drug: Budesonide 100 microgram/Actuation Powder for Inhalation Sponsors: Intech Biopharm Ltd.; GCP ClinPlus Co., Ltd.; Beijing Aicomer Pharmaceutical Technology Co., Ltd.; Key Tech; Healthcare Inc; Peking University People's Hospital; Beijing Friendship Hospital; Tianjin First Central Hospital; Bao Gang Hospital; The Affili ated Hospital of Inner Mongolia Medical University; Beijing Yi Hua Hospital Management Co., Ltd; The Second Hospital of Hebei Medical University; The First Affiliated Hospital of Shanxi Medical University; Shaanxi Provincial People's Hospital; Jining Medical Universit y; Qingdao Municipal Hospital; Daqing Oil Field Hospital; First Affiliated Hospital of Jinan University; Meizhou People's Hospital; Meiheko Central Hospital Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials